All the key secondary endpoints of the trial were met, demonstrating the “statistical significance” of the therapy.

Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 clinical trial program evaluating rocatinlimab, an investigational ...

In September 2024, a readout from a separate trial of rocatinlimab elicited mixed reactions from analysts, who found the ...

Amgen and Kyowa Kirin have shared promising results from a phase 3 programme of their investigational T-cell rebalancing ...

Amgen and Kyowa Kirin's rocatinlimab showed strong efficacy in Phase 3 trials for atopic dermatitis, achieving key endpoints ...

US biotech Amgen (Nasdaq: AMGN) and Japanese partner Kyowa Kirin (TYO: 4151) announced new results from the ongoing ROCKET ...

In the treatment of psoriasis, preliminary evidence supports the hypothesis that IL-23 inhibitors are capable of extended remissions and protection against PsA relative to other biologics.

THOUSAND OAKS, Calif. and TOKYO, March 8, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151) today announced new results from the ongoing ROCKET Phase 3 ...

Japanese drugmaker Kyowa Kirin and Swiss generics and biosimilars giant Sandoz have won approval for the partial change of their rituximab biosimilar for the treatment of refractory nephrotic syndrome ...

In a report released on March 7, Stephen Barker from Jefferies maintained a Buy rating on Kyowa Kirin Co (KYKOF – Research Report), with a ...

Amgen & Kyowa Kirin positive results from rocatinlimab phase 3 IGNITE study in adults with moderate to severe atopic dermatitis: Thousand Oaks, California Tuesday, March 11, 2025, ...